10,10-Dimethylanthrone

We are 10,10-Dimethylanthrone CAS:5447-86-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   10,10-Dimethylanthrone
CAS.NO:  5447-86-9
Synonyms:
10,10-dimethylanthracen-9-one
9(10H)-Anthracenone, 10,10-dimethyl-
10,10-Dimethylanthracen-9(10H)-on
10,10-Dimethyl-9(10H)-anthracenone
10,10-dimethylanthracen-9(10H)-one
Melitracen hydrochloride

Molecular Formula: C16H14O
Molecular Weight:  222.28200

Physical and Chemical Properties:
Density: 1.105g / cm3
Boiling point: 346.6ºC at 760mmHg
Melting point: 101-103ºC
Flash point: 149.4ºC
Refractive index: 1.59

Specification:
Appearance: White Powder
Purity:≥99.0%
Any other impurity:≤1.0%
Heavy Metals:≤20ppm
Residue on ignition:≤0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:  Intermediates of melitracen hydrochloride CAS:10563-70-9.

Related News: “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”6-bromo-2,3-dihidro-4H-cromo-4-ona CAS:49660-57-3 “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”2-(2,4-Diaminophenoxy)ethanol sulfate CAS:70643-20-8 Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies.19111-87-6 Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.